Chronic Obstructive Pulmonary Disease Drugs Market is Expected to Reach $ 14.27 bn by 2026
The Chronic Obstructive Pulmonary Disease (COPD) was valued at US $10.78 billion in the year 2018 and is estimated to reach US $14.27 billion by 2026, at a CAGR of 3.57%.
Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory lung disease that causes airflow obstruction and breathing difficulties. COPD is characterized by emphysema, chronic bronchitis, and refractory (non-reversible) asthma. Further, COPD symptoms include frequent coughing, increased breathlessness, wheezing and tightness in the chest.
The class of drugs for the treatment of COPD includes bronchodilators, leukotriene antagonists, mast cell stabilizers and immunosuppressants. The bronchodilator drugs for the treatment of COPD are Long-Acting β2 Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA), Short-Acting β2 Agonists (SABA), Short-Acting Muscarinic Antagonists (SAMA), Phosphodiesterase Inhibitors, LABA/LAMA Fixed-Dose Combinations, and SABA/SAMA Fixed-Dose Combination.
According to National Health Interview Survey Cape Town, South Africa, has the highest prevalence, affecting 22.2% of men and 16.7% of women and Germany has the lowest prevalence, 8.6% for men and 3.2%. There were around 251 million cases of COPD reported globally by WHO. Tobacco smoking is a major risk factor for COPD and approximately 20% of smokers develop the disease and about 15–20 % of COPD cases are due to occupational exposures to pollutants at the workplace. COPD is currently the fifth-leading cause of mortality worldwide. The Third National Health and Nutrition Examination Survey showed a prevalence of COPD in adults of 6.8 percent in the USA. The prevalence of COPD in Africa varies between 4% and 25% across the countries.
The major challenge was to create awareness about smoking effects and conduct De-addiction programs, counseling along with a therapeutic approach for COPD affected smokers. Currently, more than 20 pipeline drugs are under development which is expected to hit the market creating positive growth impact in the forecast period. North American & the European regions are the market leaders due to the high prevalence of COPD patients as well as the presence of major companies. However, due to a surge in the industrial activities in the Asian Pacific region, especially in China, India, Vietnam, Bangladesh, etc. are decreasing the air quality to a greater level. These regions are expected to contribute to the overall growth of the COPD population and the market growth is expected to a greater extent in the forecast period.
The key driver for the COPD market is the increasing prevalence of respiratory diseases owing to the increasing geriatric population and smoking population. Increased automotive, industrial exhaust gases are degrading air quality and have led to the increased incidence of asthma due to immense pollution, especially in the low-income population in the emerging economies. The key market restraint is high treatment cost, the growing portfolio of generic drugs, and patent expiration of key blockbuster drugs.
Major companies which develop drugs for Chronic Obstructive Pulmonary Disease (COPD) include AstraZeneca, F. Hoffmann-La Roche, Novartis AG, Merck & Co, GlaxoSmithKline Plc, Boehringer Ingelheim Gmbh, Nycomed, Abbott Laboratories, Cipla, Dr. Reddy’s Laboratories, Glenmark, Mylan, Pfizer, Ranbaxy, Sunovion, and Vectura. According to clinicaltrials.gov, there are more than 350 ongoing interventional clinical trials for the treatment of Chronic Obstructive Pulmonary Disease (COPD) at present.
- In March 2019, Novartis AG launched Ultibro Breezhaler and Seebri Breezhaler in China, for the treatment of chronic obstructive pulmonary disease.
- In April 2019, Cipla launched Niveoli in India, beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults suffering from obstructive airway diseases (OAD) such as asthma and chronic obstructive pulmonary disorder (COPD).
- In April 2019, Circassia announced FDA approval of Duaklir®, aclidinium bromide/formoterol fumarate combination maintenance treatment for COPD
Chronic Obstructive Pulmonary Disease (COPD) Market Based on Treatment Class (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn):
- Leukotriene antagonists
- Mast cell stabilizers
Chronic Obstructive Pulmonary Disease (COPD) Market Based on Distribution Channel (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn):
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Chronic Obstructive Pulmonary Disease (COPD) Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
- North America
- Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments of Chronic Obstructive Pulmonary Disease (COPD) Drugs Market.
- Provides a Comparative Analysis of Key Marketed and Pipeline Products.
- Provides Key Information on Players involved in Chronic Obstructive Pulmonary Disease (COPD) Drugs Market.
- Provides a Complete Overview of Market Segments and the Regional Outlook of Chronic Obstructive Pulmonary Disease (COPD) Drugs Market.
- Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
Download Complete TOC of the Report @ https://www.optimainsights.org/request-toc/167-chronic-obstructive-pulmonary-disease-drugs-market
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)